Muñoz-Martínez, S;
Sapena, V;
Forner, A;
Nault, J-C;
Sapisochin, G;
Rimassa, L;
Sangro, B;
... Reig, M; + view all
(2021)
Assessing the impact of COVID-19 on liver cancer management (CERO-19).
JHEP Reports
, Article 100260. 10.1016/j.jhepr.2021.100260.
(In press).
Preview |
Text
1-s2.0-S2589555921000367-main.pdf - Accepted Version Download (2MB) | Preview |
Abstract
BACKGROUND: The coronavirus 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). This project has evaluated if the schedule of LC screening or procedures has been interrupted /delayed because of the COVID-19 pandemic. MATERIAL AND METHODS: An international survey evaluated the impact of COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave. RESULTS: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia and Africa (73.7%, 17.1%, 5.3%, 2.6% and 1.3% per continent, respectively). Eighty-seven per cent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening program, 50% cancelled curative and/or palliative treatments for LC, and 44.0% cancelled the liver transplantation program. Forty-five out 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service prior to COVID-19 pandemic (n=19/37). CONCLUSION: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with LC. Modifications in screening, diagnostic and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision making.
| Type: | Article |
|---|---|
| Title: | Assessing the impact of COVID-19 on liver cancer management (CERO-19) |
| Location: | Netherlands |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.jhepr.2021.100260 |
| Publisher version: | https://doi.org/10.1016/j.jhepr.2021.100260 |
| Language: | English |
| Additional information: | This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Keywords: | BCLC, Barcelona Clinic Liver Cancer, CERO-19, Liver Cancer Outcome in the COVID-19-pandemic Project, COVID-19, ENS-CCA, European Network for the Study of Cholangiocarcinoma, Hepatocellular carcinoma, IQR, Interquartile range, LC, Liver Cancer, cholangiocarcinoma, clinical trials, liver cancer, management, nurses |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10123643 |
Archive Staff Only
 |
View Item |
